A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter Cohort Study Using Risk Factors
Takaya Maruyama1, Takao Fujisawa2, Tadashi Ishida3
1Department of Respiratory Medicine, National Hospital Organization, Mie National Hospital, Tsu.
Background:
Empiric therapy of pneumonia is currently based on the site of acquisition (community or hospital), but could be chosen, based on risk factors for multidrug-resistant (MDR) pathogens, independent of site of acquisition.
Methods:
We prospectively applied a therapeutic algorithm based on MDR risks, in a multicenter cohort study of 1089 patients with 656 community-acquired pneumonia (CAP), 238 healthcare-associated pneumonia (HCAP), 140 hospital-acquired pneumonia (HAP), or 55 ventilator-associated pneumonia (VAP).
Results:
Approximately 83% of patients were treated according to the algorithm, with 4.3% receiving inappropriate therapy. The frequency of MDR pathogens varied, respectively, with VAP (50.9%), HAP (27.9%), HCAP (10.9%), and CAP (5.2%). Those with ≥2 MDR risks had MDR pathogens more often than those with 0-1 MDR risk (25.8% vs 5.3%, P < .001). The 30-day mortality rates were as follows: VAP (18.2%), HAP (13.6%), HCAP (6.7%), and CAP (4.7%), and were lower in patients with 0-1 MDR risks than in those with ≥2 MDR risks (4.5% vs 12.5%, P < .001). In multivariate logistic regression analysis, 5 risk factors (advanced age, hematocrit <30%, malnutrition, dehydration, and chronic liver disease), as well as hypotension and inappropriate therapy were significantly correlated with 30-day mortality, whereas the classification of pneumonia type (VAP, HAP, HCAP, CAP) was not.
Conclusions:
Individual MDR risk factors can be used in a unified algorithm to guide and simplify empiric therapy for all pneumonia patients, and were more important than the classification of site of pneumonia acquisition in determining 30-day mortality.
Clinical Trials Registration:
JMA-IIA00146.
Insights
Empiric pneumonia treatment can be guided by multidrug-resistant (MDR) risk factors, not just site of acquisition. This approach simplifies therapy and proves more critical than pneumonia classification for predicting 30-day mortality.
Area of Science:
- Infectious Diseases
- Clinical Medicine
- Pharmacology
Background:
- Current empiric pneumonia therapy relies on the site of acquisition (community vs. hospital).
- An alternative approach considers risk factors for multidrug-resistant (MDR) pathogens, irrespective of acquisition site.
- This study investigates the utility of an MDR risk-based algorithm for pneumonia treatment.
Purpose of the Study:
- To evaluate a therapeutic algorithm for pneumonia based on multidrug-resistant (MDR) risk factors.
- To compare the effectiveness of MDR risk-based therapy versus site-of-acquisition-based therapy.
- To identify key factors influencing 30-day mortality in pneumonia patients.
Main Methods:
- A prospective, multicenter cohort study involving 1089 patients with various pneumonia types (CAP, HCAP, HAP, VAP).
- Application of a therapeutic algorithm prioritizing MDR risk factors for empiric treatment.
- Analysis of MDR pathogen frequency, treatment appropriateness, and 30-day mortality rates.
Main Results:
- The MDR risk-based algorithm was applied to 83% of patients, with a low rate (4.3%) of inappropriate therapy.
- MDR pathogen frequency increased with pneumonia severity: VAP (50.9%) > HAP (27.9%) > HCAP (10.9%) > CAP (5.2%).
- Patients with ≥2 MDR risks had higher MDR pathogen rates (25.8% vs. 5.3%) and 30-day mortality (12.5% vs. 4.5%) compared to those with 0-1 risk.
Conclusions:
- A unified algorithm using individual MDR risk factors can guide and simplify empiric pneumonia therapy.
- MDR risk factors are more critical than the site of pneumonia acquisition in determining 30-day mortality.
- Advanced age, specific hematocrit levels, malnutrition, dehydration, chronic liver disease, hypotension, and inappropriate therapy were significant predictors of mortality.
More Related Videos
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
23:06The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Related Concept Videos
01:26Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
01:29Therapeutic Drug Monitoring: Affecting Factors
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
02:33Initiation of Translation
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
02:33Initiation of Translation
01:09Empirical Method to Interpret Standard Deviation
This rule is used widely in statistics to calculate the proportion of data values...